Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults
Open Access
- 31 January 2018
- journal article
- editorial
- Published by Wiley in Aging Cell
- Vol. 17 (2), e12723
- https://doi.org/10.1111/acel.12723
Abstract
Administration of metformin increases healthspan and lifespan in model systems, and evidence from clinical trials and observational studies suggests that metformin delays a variety of age-related morbidities. Although metformin has been shown to modulate multiple biological pathways at the cellular level, these pleiotropic effects of metformin on the biology of human aging have not been studied. We studied ~70-year-old participants (n = 14) in a randomized, double-blind, placebo-controlled, crossover trial in which they were treated with 6 weeks each of metformin and placebo. Following each treatment period, skeletal muscle and subcutaneous adipose tissue biopsies were obtained, and a mixed-meal challenge test was performed. As expected, metformin therapy lowered 2-hour glucose, insulin AUC, and insulin secretion compared to placebo. Using FDR<0.05, 647 genes were differentially expressed in muscle and 146 genes were differentially expressed in adipose tissue. Both metabolic and nonmetabolic pathways were significantly influenced, including pyruvate metabolism and DNA repair in muscle and PPAR and SREBP signaling, mitochondrial fatty acid oxidation, and collagen trimerization in adipose. While each tissue had a signature reflecting its own function, we identified a cascade of predictive upstream transcriptional regulators, including mTORC1, MYC, TNF, TGFß1, and miRNA-29b that may explain tissue-specific transcriptomic changes in response to metformin treatment. This study provides the first evidence that, in older adults, metformin has metabolic and nonmetabolic effects linked to aging. These data can inform the development of biomarkers for the effects of metformin, and potentially other drugs, on key aging pathways.Keywords
Funding Information
- Glenn Foundation for Medical Research
- Einstein-Mount Sinai Diabetes Research Center, Albert Einstein College of Medicine
- National Institutes of Health (5P60DK20541)
- New York State Department of Health
- Burroughs Wellcome Fund
This publication has 20 references indexed in Scilit:
- Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non‐diabetic controlsDiabetes, Obesity and Metabolism, 2014
- Metformin improves healthspan and lifespan in miceNature Communications, 2013
- mTOR is a key modulator of ageing and age-related diseaseNature, 2013
- Human Ageing Genomic Resources: Integrated databases and tools for the biology and genetics of ageingNucleic Acids Research, 2012
- The Critical Role of Metabolic Pathways in AgingDiabetes, 2012
- The pyruvate dehydrogenase complex as a therapeutic target for age‐related diseasesAging Cell, 2012
- Adipose tissue remodeling and obesityJCI Insight, 2011
- Aging and chronic DNA damage response activate a regulatory pathway involving miR-29 and p53The EMBO Journal, 2011
- Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitroCell Cycle, 2009
- Overexpression of the Cytosolic Form of Phosphoenolpyruvate Carboxykinase (GTP) in Skeletal Muscle Repatterns Energy Metabolism in the MouseOnline Journal of Public Health Informatics, 2007